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29% of moderate, 6% of severe and 1% of very severe; 7) only patients in moderate,
severe and very severe groups were considered as eligible for treatment with long-
acting maintenance therapy; and 8) 53% of annual treatment persistence rate was
applied. The ex-factory price with 24.38% of discount was used for indacaterol costs
and 5% of annual discount rate was applied on the costs. Indacaterol 150g uptake
was assumed to be: 9%, 13%, 17%, 19%, 21%; and for indacaterol 300g: 1%, 2%, 3%,
4%, 4%, over 5 years consecutively. RESULTS: The number of patients eligible for
treatment with long-acting maintenance therapy in Brazil was estimated to be
around 256,040 in the first year. The annual budget impact of indacaterol through
the years was approximately: 20M, 30M, 38M, 42M and 44M (BRL) consecutively.
CONCLUSIONS: Currently none drugs are reimbursed for COPD maintenance ther-
apy by SUS. According to this analysis, considering only the costs with indacaterol,
it should have a small impact on the Ministry of Health’s budget.
PRS16
COST ANALYSIS OF HAEMOSTATIC TREATMENT WITH A FIBRIN-BASED
SPONGE VERSUS FIBRIN SEALANT IN LUNG SURGERY AND LIVER RESECTION IN
A SPANISH SETTING
Darba J1, Kaskens L2, Perez-Alvarez N2
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health, Barcelona, Spain
OBJECTIVES: To assess the health care resources used and estimate the costs as-
sociated with the use of a collagen sponge coated with human fibrinogen and
thrombin compared with fibrin sealant to improve haemostasis in lung surgery and
liver resection. METHODS: A cost-analysis of the healthcare resources used with
the administration of a fibrin-based sponge and fibrin sealant was performed.
Health care resource utilisation and unit costs associated with both treatments in
lung surgery and liver resection was obtained from literature research. Costs in-
cluded for lung surgery were drug costs, preparation and administration time and
additional hospitalisation due to post-surgery pulmonary air leakage. Costs for
liver resection included drug costs, preparation and administration time, drainage
and hospitalisation days at ward or an intensive care unit. Drug costs were ob-
tained from Spanish medication databases. All costs were referred to EUR 2010.
Based on the healthcare resource use the mean cost per patient for each treatment
was estimated. A two-way sensitivity analysis was performed determining mini-
mum and maximum mean costs per patient. RESULTS: Mean drug costs for the
fibrin-based sponge and fibrin sealant in lung surgery resulted in €275 and €345,
respectively. Total treatment costs per patient were estimated at €376 and at €509
for the fibrin-based sponge and fibrin sealant. In liver resection mean drug costs
resulted in €550 for the fibrin-based sponge and in €690 for fibrin sealant, respec-
tively. The associated total treatment costs per patient added up to approximately
€5725 for the fibrin-based sponge and €6148 for fibrin sealant. CONCLUSIONS: The
use of a fibrin-based sponge showed benefits over the use of fibrin sealant in lung
surgery and liver resection. Less use of health care resources with the application of
fibrin-based sponges versus fibrin sealant resulted in lower associated treatment
costs per patient.
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OBJECTIVES: Earlier research has shown that Hand Eczema (HE) is often work-
related, widespread, potentially disabling and costly, but often misdiagnosed and
mistreated. Severe Chronic Hand Eczema (CHE) can be particularly burdensome,
especially among severe patients refractory to therapy. We assessed cost-of-illness
of severe CHE patients refractory to topical potent corticosteroids and their prev-
alence among HE patients accessing dermatology centres. METHODS: a naturalis-
tic, multicentre study was conducted in 14 Italian dermatology centers. HE patients
aged 18 years, consecutively accessing the participating centers through a
6-month period were enrolled. Socio-demographic and clinical data were collected
for all patients, while direct, indirect costs and HRQol data were collected on severe
refractory CHE patients. HRQoL was collected with the EQ-5D and the condition-
specific Dermatology-Life-Quality-Index (DLQI, having a summary score ranging
from 0 to 30, higher score corresponds to more impaired HRQoL). Direct and indi-
rect costs data were collected through a retrospective 8-week time horizon, using
the societal perspective. RESULTS: in total 981 HE patients were enrolled (mean
ageSD39.115.1, 35.9% male), 11.0% had severe refractory CHE. DLQI meanSD
sum score was 11.36.3. With EQ-5D 96.2% of patients reported moderate or severe
pain/discomfort, 73.1% problems with usual activities, 55.8% anxiety/depression
and 52.9% problems with self-care. VAS meanSD60.423.3. On average hospi-
talizations cost 67.3€/patient-month, travels cost 43.4€/patient-month, specialist
visits cost 41.0€/patient-month, other products (gloves, gauze bandage, vacuum
cleaner, cosmetics) cost 27.2€/patient-month, diagnostic exams cost 19.6€/patient-
month, non pharmacological therapy (emollients, galenic products, soap, UV-ther-
apy) cost 18.7€/patient-month, pharmacological therapy cost 18.2€/patient-month.
Patients lost on average 4.9 workdays/patient-month for reasons attributable to
their disease. CONCLUSIONS: Approximately one tenth of HE patients accessing
dermatology centers have severe refractory CHE. These generate high costs to
manage their condition, and have a significant productivity loss and a poor HRQoL.
An appropriate diagnosis and treatment is necessary to efficiently manage the
disease.
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Cystic fibrosis (CF) is a genetic disease characterized by progressive lung disease. In
the US, the median age of death is 27 years. Published studies of the cost of CF by
severity are outdated and do not report costs stratified jointly by age and FEV1.
OBJECTIVES: To gain understanding of the current economic burden of disease, we
estimated the cost of CF by severity and age group. METHODS: We used an admin-
istrative claims database from a large US health plan to estimate mean annual total
costs for patients with CF by age category (in 5-year increments) for patients ages 5
and older from 2004 to 2008. As claims data do not contain information on FEV1, we
derived the proportions of patients with mild (FEV1 70% predicted), moderate
(40-69% predicted), and severe (40% predicted) CF by age category using data from
the CF Foundation Registry. We then estimated the ratios of costs for moderate and
severe patients relative to mild patients using data from Lieu et al. (1999). Finally,
we estimated treatment costs for patients with CF by age and FEV1 using propor-
tions of patients in each FEV1 category, relationships between cost and disease
severity, and costs by age from the database analysis. RESULTS: Preliminary esti-
mated annual costs of care were $30,000, $57,000, and $215,000 for patients with
mild, moderate, and severe disease, respectively. For all severity groups, costs were
highest among children 10-14 years, and decreased with increasing age through
age 45 years. Estimated annual costs of care for patients with CF ranged from
$15,600 for mild patients aged 40-44 years to $343,900 for severe patients aged 10-14
years. CONCLUSIONS: Annual costs of CF care are highly variable by age and dis-
ease severity. Interventions that keep patients out of the severe disease state may
save costs.
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OBJECTIVES: Current asthma management guidelines are based on the level of
asthma control. This study was designed to estimate quality of life and health care
costs according to the patients’ level of asthma control in France and in Spain in
real-life setting.METHODS:On a 1-month and a 3-months period. An observational
retrospective bottom-up cost of illness study (XX2113553) was conducted simulta-
neously in both countries among adults with asthma. Patients were recruited by
samples of general practitioners during four quarterly waves throughout the year
2010 avoiding thus a seasonal bias. Asthma control was evaluated using the auto-
test Asthma Control Test (ACTTM) for a one month period and 2009 GINA’s asthma
control criteria for a three months period. Quality of life (QoL) was assessed using
EQ-5D profile. Costs (direct and indirect) were evaluated from a societal
perspective. RESULTS: A total of 2671 patients (France: 1154; Spain: 1517) were
enrolled in the survey. Asthma was determined to be well-controlled (ACT  20) in
54.2% [IC 95%: 50.9% - 57.7%] and 58.8% [IC95: 56.2% - 61.3%] of French and Spanish
patients respectively. In both countries, average EQ-5D scores were higher for pa-
tients with well-controlled asthma (France: 0.9 vs. 0.7, p0.0001; Spain: 0.9 vs. 0.6,
p0.0001). Total costs of asthma varied accordingly to asthma control in both
countries. The average total cost (Euros/month/patient) of well-controlled asthma
was 57 € (467) in France and 82 € (171) in Spain compared with 111 € (618)
(p0.0001) and 221 € (323) (p0.0001) respectively for not well-controlled asthma.
Similar variations were observed using the GINA’s criteria on a 3-months period.
CONCLUSIONS: Results suggested that a poor asthma control is associated with
higher costs and lower QoL in patients with asthma in both countries. Improving
the control of asthma could eventually be associated to a decrease of the burden of
asthma.
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OBJECTIVES: To examine the relationship between costs and severity of COPD, and
to up-date the economical burden of COPD for the Swedish society.METHODS: The
study sample was identified in 2009 from earlier clinical examinations of general
population cohorts within the OLIN (Obstructive Lung Disease in Northern Sweden)
studies. A number of 993 subjects were identified as having COPD (GOLD spiromet-
ric criteria). In 2009-2010, telephone interviews on resource utilization were made
to a sample of 244 subjects, stratified by disease severity. Interviews were per-
formed quarterly to minimize the risk of recall bias. Costs were calculated by ap-
plying unit costs from 2010. The prevalence for each disease severity was multi-
plied with the mean costs in order to calculate total societal costs. Non-parametric
tests were used for testing the influence of COPD severity on costs in 2010, and
when comparing the results with a previous study in 1999. RESULTS: A highly
significant relationship was found between disease severity and costs. The mean
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